ATE399558T1 - Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln - Google Patents

Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln

Info

Publication number
ATE399558T1
ATE399558T1 AT04764686T AT04764686T ATE399558T1 AT E399558 T1 ATE399558 T1 AT E399558T1 AT 04764686 T AT04764686 T AT 04764686T AT 04764686 T AT04764686 T AT 04764686T AT E399558 T1 ATE399558 T1 AT E399558T1
Authority
AT
Austria
Prior art keywords
tumoral
combination
formulations containing
antitumoral agents
alone
Prior art date
Application number
AT04764686T
Other languages
English (en)
Inventor
Laura Ferro
Massimo Iacobelli
Paul Richardson
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Application granted granted Critical
Publication of ATE399558T1 publication Critical patent/ATE399558T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04764686T 2003-09-05 2004-08-27 Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln ATE399558T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
US53934404P 2004-01-28 2004-01-28

Publications (1)

Publication Number Publication Date
ATE399558T1 true ATE399558T1 (de) 2008-07-15

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764686T ATE399558T1 (de) 2003-09-05 2004-08-27 Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln

Country Status (23)

Country Link
US (2) US8551967B2 (de)
EP (1) EP1660100B1 (de)
JP (1) JP4671962B2 (de)
KR (1) KR20060061367A (de)
CN (1) CN100490820C (de)
AT (1) ATE399558T1 (de)
AU (1) AU2004269896B2 (de)
BR (1) BRPI0414114A (de)
CA (1) CA2537226C (de)
DE (1) DE602004014787D1 (de)
DK (1) DK1660100T3 (de)
ES (1) ES2308223T3 (de)
IL (1) IL173785A0 (de)
IS (1) IS8334A (de)
IT (1) ITMI20031714A1 (de)
MX (1) MXPA06002489A (de)
NO (1) NO20061402L (de)
PT (1) PT1660100E (de)
RS (1) RS20060154A (de)
RU (1) RU2348413C2 (de)
UA (1) UA83500C2 (de)
WO (1) WO2005023273A1 (de)
ZA (1) ZA200601852B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070120953A (ko) * 2005-03-03 2007-12-26 젠티엄 에스피에이 항암활성을 갖는 제제
EP1872787A1 (de) * 2006-06-27 2008-01-02 Gentium S.p.A. Verwendung von Defibrotide als Heparanasehemmer
EP2103689A1 (de) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetische Phosphodiester-Oligonukleotide und deren therapeutische Verwendungen
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR20190112197A (ko) 2012-06-22 2019-10-02 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (de) * 2014-11-27 2016-06-01 Gentium S.p.A. Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
EP3661484A1 (de) * 2017-08-03 2020-06-10 Jazz Pharmaceuticals Ireland Limited Formulierungen mit einer nukleinsäure in hoher konzentration
EP3773608A1 (de) 2018-04-12 2021-02-17 Jazz Pharmaceuticals, Inc. Defibrotid zur vorbeugung und behandlung des zytokinfreisetzungssyndroms und der neurotoxizität im zusammenhang mit immundepletion
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
EP4110287A1 (de) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Abgabe von niedrigviskosen formulierungen
WO2022234101A1 (en) 2021-05-06 2022-11-10 Jazz Pharmaceuticals Ireland Limited Defibrotide for the treatment and prevention of acute respiratory distress syndrome

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
EP1202750A4 (de) * 1997-04-28 2002-10-16 Arsinur Burcoglu Verfahren zur behandlung von hiv-infektionen und von deren opportunistischen infektionen
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
EP1206234A4 (de) * 1999-06-03 2005-06-01 Jessie L S Au Verfahren und zusammensetzung zum einstellen der zellproliferation und des zelltodes
EP1406930A4 (de) * 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "isolierte moleküle mit sulfatierte gruppierungen enthaltenden epitopen, antikörper gegen solche epitope und verwendungen davon"
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
WO2003027313A2 (en) 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
CN1304011C (zh) * 2002-05-31 2007-03-14 雷根斯堡大学医学院 保护性寡聚脱氧核糖核苷酸的制药用途
BR0312483A (pt) * 2002-07-01 2005-08-09 Savient Pharmaceuticals Inc Anticorpos e seus usos
US20060293256A1 (en) 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
KR20070120953A (ko) 2005-03-03 2007-12-26 젠티엄 에스피에이 항암활성을 갖는 제제
EP1872787A1 (de) 2006-06-27 2008-01-02 Gentium S.p.A. Verwendung von Defibrotide als Heparanasehemmer
EP1982722A1 (de) 2007-04-16 2008-10-22 Gentium S.p.A. Verwendung von Oligotid zur Behandlung von Nierenerkrankungen

Also Published As

Publication number Publication date
BRPI0414114A (pt) 2006-10-31
ITMI20031714A1 (it) 2005-03-06
RU2348413C2 (ru) 2009-03-10
MXPA06002489A (es) 2006-06-20
CA2537226C (en) 2016-05-03
RU2006109210A (ru) 2007-10-10
DE602004014787D1 (de) 2008-08-14
JP4671962B2 (ja) 2011-04-20
CN1845746A (zh) 2006-10-11
EP1660100A1 (de) 2006-05-31
JP2007504194A (ja) 2007-03-01
KR20060061367A (ko) 2006-06-07
NO20061402L (no) 2006-03-28
RS20060154A (en) 2008-08-07
CN100490820C (zh) 2009-05-27
ES2308223T3 (es) 2008-12-01
IL173785A0 (en) 2006-07-05
PT1660100E (pt) 2008-10-14
CA2537226A1 (en) 2005-03-17
US20140005256A1 (en) 2014-01-02
US8551967B2 (en) 2013-10-08
EP1660100B1 (de) 2008-07-02
DK1660100T3 (da) 2008-11-10
WO2005023273A1 (en) 2005-03-17
ZA200601852B (en) 2007-06-27
US20060211646A1 (en) 2006-09-21
UA83500C2 (uk) 2008-07-25
AU2004269896A1 (en) 2005-03-17
AU2004269896B2 (en) 2009-11-19
IS8334A (is) 2006-02-28

Similar Documents

Publication Publication Date Title
IL173785A0 (en) Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
SG155189A1 (en) Novel fenofibrate formulations and related methods of treatment
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell&#39;epidermide
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
RS50510B (sr) Formulacije koje sadrže ekteinascidin i disaharid
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
ATE286664T1 (de) Pharmazeutische oder diätetische zusammensetzungen aus pilzen und deren verwendung
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
SI1893237T1 (sl) Farmacevtska zmes ki vsebuje organopolisiloksan elastomer in učinkovino v obliki raztopine
WO2006033713A3 (en) Methods for ciprofloxacin inhalation
MX2007011381A (es) Composicion de espirulinas rica en principios activos, su proceso de obtencion y su utilizacion.
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
TW200505437A (en) Composition possessing autonomic nerve function regulating action and use thereof
AR038560A1 (es) Una composicion antitranspirante/ desodorante
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
CA105215S (en) Packaging with cosmetic composition
BRPI0417265A (pt) composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna
SE0203817D0 (sv) New composition
MX2007004187A (es) Compuestos organicos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1660100

Country of ref document: EP